NASDAQ:TSVT - Nasdaq - US9013841070 - Common Stock - Currency: USD
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by 2seventy bio, Inc. (NASDAQ: TSVT) and its board of directors concerning...
Mentions: BMY
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such...
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 2seventy bio, Inc....